20/20 GeneSystems

20/20 GeneSystems

Early Stage

Artificial intelligence-powered diagnostics for cancer & COVID-19

Artificial intelligence-powered diagnostics for cancer & COVID-19

Overview

Raised to Date: Raised: $3,792,229

Total Commitments ($USD)

Platform

SeedInvest

Start Date

08/16/2018

Close Date

10/31/2020

Min. Goal
$10
Max. Goal
$14,700,000
Min. Investment

$502

Security Type

Equity - Preferred

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share

$3.53

Pre-Money Valuation

$38,500,000

Rolling Commitments ($USD)

Status
Funded
Reporting Date

10/31/2020

Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$4,699

# of Investors

1,710

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2000

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Location

Rockville, Maryland

20/20 GeneSystems, with a pre-money valuation of $38.5 million, is raising funds on SeedInvest through Reg A+ crowdfunding. It is a diagnostics company with a successful track record in cancer detection with its AI-powered multi-cancer blood test, OneTest. The company has recently launched CoronaCheck; its FDA authorized antibody lab test for COVID-19 antibodies. 20/20 GeneSystems was founded by Jonathan Cohen and has raised over $10 million in previous rounds of financing. The current round of funding has round size of $14,700,000, and the proceeds will be used for sales and marketing, research and development, intellectual property development and protection, and cybersecurity and patient privacy protections. 20/20 GeneSystems has already sold over 70,000 COVID-19 antibody tests since its launch in March 2020 and generated over $1.2 million in revenue.
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
20/20 GeneSystems 12/20/2022 StartEngine $58,400,000 $232,704 Convertible Note Funded RegCF
20/20 GeneSystems 06/26/2021 StartEngine $38,500,000 $2,903,017 Equity - Preferred Funded RegA+
20/20 GeneSystems 10/31/2020 SeedInvest $38,500,000 $3,792,229 Equity - Preferred Funded RegA+
20/20 GeneSystems 12/13/2017 Microventures $23,000,000 $1,064,807 Equity - Preferred Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.

Create your first portfolio

Create your own startup investment portfolio on KingsCrowd.

Track all of your startup investments in one place using our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
20/20 GeneSystems on SeedInvest
Platform: SeedInvest
Security Type: Equity - Preferred
Valuation: $38,500,000
Price per Share: $3.53

Follow company

Follow 20/20 GeneSystems on SeedInvest

Buy 20/20 GeneSystems's Deal Report

Warning: according to the close date for this deal, 20/20 GeneSystems may no longer be accepting investments.

20/20 GeneSystems Deal Report

Get KingsCrowd’s comprehensive report on 20/20 GeneSystems including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether 20/20 GeneSystems is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the 20/20 GeneSystems deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge